AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03889418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic medical recorded clinical decision support [EMR CDS]
Description: The opioid management tool has quick links to the Opioid Risk Tool (ORT), health maintenance reminders for risk mitigation tasks (pain management agreements; urine drug screening; prescribing naloxone); Pain Scale and depression/anxiety screen. The frequency with which providers are prompted to complete mitigation tasks is based on patients' level of risk for aberrant drug behavior defined by the ORT score. Additionally, the EMR CDS flags patients as high risk if one of the following criteria are met: (1) co-prescriptions for benzodiazepines; (2) active diagnosis of substance abuse in the last 12 months; or (3) MEDD >=90 mg. The ORT score, morphine equivalent daily dose (MEDD), and hyperlinks to the Louisiana pharmacy drug monitoring program data are visible in the prescription writer. If MEDD >=90 mg, the calculated MEDD is displayed in red font to alert the prescribing provider of high dosage. An Epic banner appears in charts to alert providers of existing pain management agreements.
Study NCT03889418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stepped opioid collaborative care model [CCM]
Description: The licensed clinical social worker (LCSW) will provide counseling services as indicated (behavioral activation, psychotherapy, crisis planning, facilitating connection to substance abuse counseling and treatment); meet weekly with the consulting psychiatrist for complex case review and care plan adjustments; and supervise the community health worker (CHW) case management and depression/anxiety care management activities. The CHW will update assets and barriers to recovery and self-management and help patients navigate community resources. The clinical pharmacist will review and reconcile active medication lists, assess medication side effects, drug interactions and adverse events; monitor analgesia; recommend algorithm based anti-depression medication titration as indicated. The consulting psychiatrist will directly co-manage patients with severe mental illness, substance abuse and complex medication regimens.
Study NCT02115191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate
Description: After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
Study NCT02115191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical reintervention
Description: The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
Study NCT03832933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: 16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
Study NCT03832933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Protein Diet
Description: 16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
Study NCT01527448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (seroquel)
Description: During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
Study NCT03911609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
Study NCT03911609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Task
Description: The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
Study NCT03297359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: daily subcutaneous injection of weight-adjusted dalteparin
Study NCT02779582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone
Description: The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
Study NCT04337905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHD-VR diagnosis tool
Description: Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments.
Study NCT04337905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ADHD-VR diagnosis tool
Description: Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments.
Study NCT03415971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG befor denture treatment
Study NCT02779582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill with no effect
Study NCT03797976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIP and MEP
Description: Pre-op, Post-op of, 1 month after surgery, 3 months after surgery
Study NCT03208959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1090
Description: IDO/TDO inhibitor
Study NCT03500939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical oxygen
Description: inhalation of 100% oxygen at high flow via a sealed non-rebreather face-mask with reservoir
Study NCT03500939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: e.g. thrombectomy, thrombolysis
Study NCT03500939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: e.g. thrombectomy, thrombolysis
Study NCT03974594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Tablets
Description: Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
Study NCT03974594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle
Study NCT04033939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Study NCT04033939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT04033939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03974152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subox Mini C with Avail 18 mg nicotine salt (protonated)
Description: Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine salt (protonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
Study NCT03974152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subox Mini C with Avail 18 mg nicotine (unprotonated)
Description: Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine (unprotonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
Study NCT03974152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own brand cigarette
Description: Participants will be instructed to take one puff of a cigarette matching their typical brand every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
Study NCT02925065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-traditional group guitar instruction
Description: A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
Study NCT02047942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Center-based cardiac rehabilitation
Study NCT02047942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based training with telemonitoring guidance
Study NCT03845179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline infusion
Study NCT03845179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusion
Study NCT03845179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GIP receptor antagonist
Description: Used for infusion on study days
Study NCT03845179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GIP receptor antagonist
Description: Used for infusion on study days
Study NCT03845179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitor
Description: Oral administration of DPP-4 inhibitor in active treatment period
Study NCT03845179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Oral administration of placebo tablet in placebo treatment period
Study NCT04050332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair Walking
Description: Walking up and down stairs for four minutes at a comfortable pace
Study NCT03454633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the temperature of hypothermic circulatory arrest
Description: Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
Study NCT03454633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the temperature of hypothermic circulatory arrest
Description: Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
Study NCT01945099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm
Study NCT01945099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm
Study NCT01945099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronidase
Study NCT01945099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro-PH20
Study NCT02323906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Investigational new drug
Study NCT02323906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Kinase inhibitor
Study NCT04199117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
Study NCT04199117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination nicotine patch and nicotine mini-lozenge treatment
Description: Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
Study NCT04199117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary incentives for initiating treatment
Description: Participants randomized to this intervention will earn an incentive each time they complete a first counseling session in an available treatment, up to 2 rounds of counseling per year, and up to 4 rounds of counseling over 2 years of enrollment.
Study NCT04199117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated tailored outreach
Description: Participants randomized to this intervention will receive 5 tailored letters delivered every 4-6 months. Letter content will be tailored to participant demographics and use of study treatment, and personalized with references to their primary care teams and tobacco care manager. Letters offer encouragement to quit and information about how to access available treatments.
Study NCT04199117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management
Description: Participants randomized to this intervention will receive 5 live, proactive phone calls lasting 10-15 minutes from as assigned Tobacco Care Manager who will provide manualized support and motivational encouragement, discuss available treatment options, and inform the participant how to initiate treatment when ready to quit.
Study NCT02883673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jada System
Description: It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
Study NCT01901991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radioactive seed localization (RSL)
Description: Localization of nonpalpable breast lesions with Radioactive seed localization
Study NCT01901991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wire-guided localization (WGL)
Description: Localization of nonpalpable breast lesions with Wire-guided localization
Study NCT04199117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wisconsin Tobacco Quit Line referral
Description: This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
Study NCT03415971 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EMG befor denture treatment
Study NCT04199117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wisconsin Tobacco Quit Line referral
Description: This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
Study NCT04199117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care provider referral
Description: This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
Study NCT04199117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care provider referral
Description: This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
Study NCT04199117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Untailored outreach
Description: Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
Study NCT00500409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteoform
Description: Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
Study NCT00500409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHELCAL
Description: Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
Study NCT04340414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow ECMO driving by CVVH machine
Description: With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
Study NCT02424565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IODEX® balm
Description: 2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
Study NCT02424565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo balm
Description: 2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
Study NCT03790085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone tablet
Study NCT03790085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine tablet
Study NCT03790085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablet
Study NCT01518452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed JM working memory training
Description: daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day